<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02388568</url>
  </required_header>
  <id_info>
    <org_study_id>Eisai-819111</org_study_id>
    <nct_id>NCT02388568</nct_id>
  </id_info>
  <brief_title>Lifestyle Modification and Lorcaserin for Weight Loss Maintenance</brief_title>
  <official_title>A Randomized Controlled Trial of Lifestyle Modification and Lorcaserin for Weight Loss Maintenance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed 12-month randomized controlled trial will assess the efficacy of lifestyle
      counseling, combined with lorcaserin (10 mg BID) or placebo, in maintaining weight loss
      achieved during a prior 14-week dietary run-in.

      14-week run-in. To qualify for randomization, participants must lose ≥5% of initial weight in
      the 14-week dietary run-in. This loss will be achieved with the provision of weekly, group
      lifestyle counseling, which includes a 1000-1200 kcal/day portion-controlled diet that
      combines four daily servings of a liquid diet (HMR shakes) with an evening meal of a
      frozen-food entree (and a fruit and vegetable serving). More than 70% of participants are
      expected to achieve the 5% criterion loss during the 14-week run-in.

      A total of 182 women and men with a BMI ≥33 and ≤55 kg/m2, without co-morbidities, or ≥30 and
      ≤55 kg/m2 (with a co-morbid cardiovascular disease (CVD) condition) will be enrolled in the
      4-month run-in period. Prior to enrollment, all participants will have a history, physical
      exam, electrocardiogram (EKG), and appropriate blood tests. They will attend weekly group
      sessions for 14 weeks. Participants will have a brief medical visit at week 8 to check their
      health and blood tests will be repeated. The investigators anticipate that 136 (75%)
      participants will lose 5% or more of initial weight and qualify for randomization.
      Participants who do not lose 5% will be provided a list of weight loss resources (e.g., other
      programs) to facilitate their continued weight management.

      12-month randomized trial with lorcaserin. A total of 136 participants who have lost 5% or
      more of initial weight in the run-in period will be randomly assigned, in double-blind
      fashion, to lorcaserin (10 mg BID) or matching placebo. To be eligible, participants must
      have a BMI (after prior weight loss) ≥30 kg/m2 (without co-morbidities) or greater than or
      equal to ≥27 (with a co-morbidity). Randomization will be performed by the Investigational
      Drug Service at the Hospital of the University of Pennsylvania. Prior to randomization, all
      participants will complete a second brief history and physical examination, as well as an EKG
      and blood tests. Medication will be dispensed at the randomization visit and at brief medical
      visits that follow. Over the 1 year, all participants will participate in 16 group lifestyle
      modification classes designed for weight loss maintenance, approximately half of which will
      be delivered by group conference call.

      Primary outcome measure. The primary endpoint is change in body weight (in kg), as measured
      from randomization to month 12. The co-primary end-point is the percentage of participants in
      the two groups that, at month 12, maintained the ≥5% reduction in body weight achieved during
      the 14-week dietary run-in period. Secondary efficacy endpoints include changes in CVD risk
      factors, glycemic control, and quality of life, as measured from randomization to month 12.
      Exploratory endpoints include changes in these CVD and related outcomes, as measured at the
      start of the 14-week run-in period to month 12. The investigators also will examine the
      percentage of participants in the two groups who at month 12 achieved losses of ≥5%, ≥10%,
      and ≥15% of initial weight, as measured from the start of the run-in period.

      Safety endpoints will include physical examination, electrocardiogram, adverse events (AEs),
      standard laboratory tests, and mental health assessed by the Columbia Suicidality Severity
      Rating Scale (C-SSRS) and Patient Health Questionnaire (PHQ-9).

      Statistical Analysis. The planned sample size of 136 participants, with a 1:1 randomization
      ratio, assumes a 20% drop-out rate (at month 12) and was estimated to be adequate to evaluate
      the primary endpoint with power ≥90% (P=0.05, two-sided test). The investigators predict a
      difference in weight change between the two groups (from randomization to month 12) of 4 kg
      (SD=3.5). Pre-specified data analysis will be performed on the full analysis set, comprising
      all randomized individuals exposed to trial drug with at least one post-randomization weight
      assessment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">June 2017</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Weight (kg)</measure>
    <time_frame>52 weeks post-randomization</time_frame>
    <description>This is the change in weight from randomization to week 52. This does not include the weight loss in the 14-week LCD.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion Maintaining &gt;= 5% Loss of Initial Weight</measure>
    <time_frame>52 weeks post-randomization</time_frame>
    <description>This is the number of participants who maintained &gt;=5% loss of initial weight in the randomization to week 52 trial period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body Weight (% Change)</measure>
    <time_frame>52 weeks post-randomization</time_frame>
    <description>The % change in body weight from randomization to week 52.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion Maintaining &gt;= 10% Loss of Initial Weight</measure>
    <time_frame>52 weeks post-randomization</time_frame>
    <description>This is the number of participants who maintained &gt;=10% loss of initial weight in the randomization to week 52 trial period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Weight</measure>
    <time_frame>-14 week (start of LCD program) to week 52</time_frame>
    <description>This is the change in weight from baseline (screening visit) to the final week 52 medical assessment visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Weight (% Change)</measure>
    <time_frame>-14 week (start of LCD program) to week 52</time_frame>
    <description>This is the change in weight from the baseline (screening visit) to the final week 52 medical assessment visit.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">137</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Lorcaserin plus Lifestyle Modification</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo plus Lifestyle Modification</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lorcaserin</intervention_name>
    <description>Lorcaserin plus Lifestyle Modification</description>
    <arm_group_label>Lorcaserin plus Lifestyle Modification</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo plus Lifestyle Modification</description>
    <arm_group_label>Placebo plus Lifestyle Modification</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (for the Randomized Controlled Trial)

          1. Participants must have lost ≥ 5% of initial weight in the group lifestyle modification
             program (during the 14-week diet run-in period).

          2. Participants must have a BMI ≥ 30 and ≤ 55 kg/m² or have a BMI ≥ 27 kg/m² with a
             obesity-related co-morbid condition

          3. Age ≥ 21 years and ≤ 65

          4. Eligible female patients will be:

               -  non-pregnant, evidenced by a negative urine dipstick pregnancy test

               -  non-lactating

               -  surgically sterile or postmenopausal, or they will agree to continue to use an
                  accepted method of birth control during the study

          5. Participants must have a primary care provider (PCP) who is responsible for providing
             routine care and have a reliable telephone service with which to participate in
             conference calls

        Exclusion Criteria:

          1. Pregnant or nursing (or plans to become pregnant in the next 18 months)

          2. Current major depressive episode, active suicidal ideation, or history of suicide
             attempts

          3. Use in the past 14 days of monoamine oxidase inhibitors, selective serotonin reuptake
             inhibitors (SSRI), serotonin-norepinephrine reuptake inhibitors (SNRI), tricyclics,
             lithium, triptans, antipsychotics, cabergoline, linezolid, tramadol, dextromethorphan,
             tryptophan, bupropion, St. John's Wort, or medicines to treat erectile dysfunction

          4. Uncontrolled hypertension (systolic blood pressure ≥ 160 mm Hg, or diastolic blood
             pressure ≥ 100 mm Hg)

          5. Type 1 diabetes or type 2 diabetes

          6. A fasting glucose ≥ 126 mg/dl or HbA1c ≥ 6.5

          7. Recent history of cardiovascular disease (e.g., myocardial infarction or stroke within
             the past 6 months), congestive heart failure, or heart block greater than first degree

          8. Clinically significant hepatic or renal disease

          9. Thyroid disease not controlled

         10. History of malignancy (except for non-melanoma skin cancer)

         11. Use of medications known to induce significant weight loss/gain, including chronic use
             of oral steroids

         12. Psychiatric hospitalization within the past 6 months

         13. Self-reported alcohol or substance abuse within the past 12 months, including at-risk
             drinking (current consumption of ≥ 14 alcoholic drinks per week)

         14. Loss of ≥ 10 lb of body weight within the past 3 months

         15. History of (or plans for) bariatric surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas A Wadden, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert I Berkowitz, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylvania Center for Weight and Eating Disorders</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>January 29, 2015</study_first_submitted>
  <study_first_submitted_qc>March 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2015</study_first_posted>
  <results_first_submitted>February 26, 2018</results_first_submitted>
  <results_first_submitted_qc>May 10, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">June 11, 2018</results_first_posted>
  <last_update_submitted>May 10, 2018</last_update_submitted>
  <last_update_submitted_qc>May 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Weight Loss</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 25, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/68/NCT02388568/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 19, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/68/NCT02388568/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Lorcaserin Plus Lifestyle Modification</title>
          <description>Lorcaserin: Lorcaserin plus Lifestyle Modification</description>
        </group>
        <group group_id="P2">
          <title>Placebo Plus Lifestyle Modification</title>
          <description>Placebo: Placebo plus Lifestyle Modification</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
                <participants group_id="P2" count="68"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lorcaserin Plus Lifestyle Modification</title>
          <description>Lorcaserin: Lorcaserin plus Lifestyle Modification</description>
        </group>
        <group group_id="B2">
          <title>Placebo Plus Lifestyle Modification</title>
          <description>Placebo: Placebo plus Lifestyle Modification</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="69"/>
            <count group_id="B2" value="68"/>
            <count group_id="B3" value="137"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.4" spread="10.5"/>
                    <measurement group_id="B2" value="47.7" spread="9.8"/>
                    <measurement group_id="B3" value="46.1" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="118"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiracial or other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="168.8" spread="8.6"/>
                    <measurement group_id="B2" value="165.7" spread="9.4"/>
                    <measurement group_id="B3" value="167.2" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Weight (kg)</title>
        <description>This is the change in weight from randomization to week 52. This does not include the weight loss in the 14-week LCD.</description>
        <time_frame>52 weeks post-randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lorcaserin Plus Lifestyle Modification</title>
            <description>Lorcaserin: Lorcaserin plus Lifestyle Modification</description>
          </group>
          <group group_id="O2">
            <title>Placebo Plus Lifestyle Modification</title>
            <description>Placebo: Placebo plus Lifestyle Modification</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Weight (kg)</title>
          <description>This is the change in weight from randomization to week 52. This does not include the weight loss in the 14-week LCD.</description>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="0.8"/>
                    <measurement group_id="O2" value="2.5" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Proportion Maintaining &gt;= 5% Loss of Initial Weight</title>
        <description>This is the number of participants who maintained &gt;=5% loss of initial weight in the randomization to week 52 trial period.</description>
        <time_frame>52 weeks post-randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lorcaserin Plus Lifestyle Modification</title>
            <description>Lorcaserin: Lorcaserin plus Lifestyle Modification</description>
          </group>
          <group group_id="O2">
            <title>Placebo Plus Lifestyle Modification</title>
            <description>Placebo: Placebo plus Lifestyle Modification</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion Maintaining &gt;= 5% Loss of Initial Weight</title>
          <description>This is the number of participants who maintained &gt;=5% loss of initial weight in the randomization to week 52 trial period.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Weight (% Change)</title>
        <description>The % change in body weight from randomization to week 52.</description>
        <time_frame>52 weeks post-randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lorcaserin Plus Lifestyle Modification</title>
            <description>Lorcaserin: Lorcaserin plus Lifestyle Modification</description>
          </group>
          <group group_id="O2">
            <title>Placebo Plus Lifestyle Modification</title>
            <description>Placebo: Placebo plus Lifestyle Modification</description>
          </group>
        </group_list>
        <measure>
          <title>Body Weight (% Change)</title>
          <description>The % change in body weight from randomization to week 52.</description>
          <units>% change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="0.8"/>
                    <measurement group_id="O2" value="2.2" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion Maintaining &gt;= 10% Loss of Initial Weight</title>
        <description>This is the number of participants who maintained &gt;=10% loss of initial weight in the randomization to week 52 trial period.</description>
        <time_frame>52 weeks post-randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lorcaserin Plus Lifestyle Modification</title>
            <description>Lorcaserin: Lorcaserin plus Lifestyle Modification</description>
          </group>
          <group group_id="O2">
            <title>Placebo Plus Lifestyle Modification</title>
            <description>Placebo: Placebo plus Lifestyle Modification</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion Maintaining &gt;= 10% Loss of Initial Weight</title>
          <description>This is the number of participants who maintained &gt;=10% loss of initial weight in the randomization to week 52 trial period.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Weight</title>
        <description>This is the change in weight from baseline (screening visit) to the final week 52 medical assessment visit.</description>
        <time_frame>-14 week (start of LCD program) to week 52</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lorcaserin Plus Lifestyle Modification</title>
            <description>Lorcaserin: Lorcaserin plus Lifestyle Modification</description>
          </group>
          <group group_id="O2">
            <title>Placebo Plus Lifestyle Modification</title>
            <description>Placebo: Placebo plus Lifestyle Modification</description>
          </group>
        </group_list>
        <measure>
          <title>Body Weight</title>
          <description>This is the change in weight from baseline (screening visit) to the final week 52 medical assessment visit.</description>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.4" spread="0.9"/>
                    <measurement group_id="O2" value="-7.5" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Weight (% Change)</title>
        <description>This is the change in weight from the baseline (screening visit) to the final week 52 medical assessment visit.</description>
        <time_frame>-14 week (start of LCD program) to week 52</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lorcaserin Plus Lifestyle Modification</title>
            <description>Lorcaserin: Lorcaserin plus Lifestyle Modification</description>
          </group>
          <group group_id="O2">
            <title>Placebo Plus Lifestyle Modification</title>
            <description>Placebo: Placebo plus Lifestyle Modification</description>
          </group>
        </group_list>
        <measure>
          <title>Body Weight (% Change)</title>
          <description>This is the change in weight from the baseline (screening visit) to the final week 52 medical assessment visit.</description>
          <units>% change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.8" spread="0.8"/>
                    <measurement group_id="O2" value="-6.6" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events for phase 2 of the trial were reported from the time of randomization to 13 months after randomization. Safety assessments included recording adverse events at all clinic visits; a physical examination, fasting blood test, and urine pregnancy test (as appropriate) at randomization, and weeks 24 and 52 of phase 2; and nine brief medical visits to measure vital signs, review health, and administer the Columbia-Suicide Severity Rating Scale.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Lorcaserin Plus Lifestyle Modification</title>
          <description>Lorcaserin: Lorcaserin plus Lifestyle Modification</description>
        </group>
        <group group_id="E2">
          <title>Placebo Plus Lifestyle Modification</title>
          <description>Placebo: Placebo plus Lifestyle Modification</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Sialolithiasis/sialadenitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Asthma Exacerbation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Lung nodules</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Staph cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal injury</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Asthma exacerbation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jena Shaw Tronieri</name_or_title>
      <organization>The University of Pennsylvania's Center for Weight and Eating Disorders</organization>
      <phone>215-746-5045</phone>
      <email>jena.tronieri@pennmedicine.upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

